Compare Incyte Corporation (INCY) vs United Airlines Holdings Inc (UAL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs United Airlines Holdings Inc — how do they compare? Incyte Corporation trades at $120.95 (market cap $24.54B), while United Airlines Holdings Inc trades at $125.04 (market cap $41.00B). The key difference: United Airlines Holdings Inc is the larger of the two by market cap. Which is the better fit depends on your goals.
| INCY | UAL | |
|---|---|---|
Market Cap | $24.54B | $41.00B |
Sector | Health | Industrials |
52-Week High | $129.93 | $136.11 |
52-Week Low | $81.61 | $85.21 |
Enterprise Value | $20.04B | $58.03B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $121.55, near its consensus price target of $122.82, with a bullish technical signal and strong recent earnings beats. Revenue grew to $5.14B in 2025, with net income surging to $1.29B, reflecting robust profitability. The company raised its 2026 revenue outlook following strong Q2 results and positive developments like EU approval for Opzelura.
Outlook is positive with solid fundamentals and analyst support, though risks include competitive pressures and reliance on key products. The stock offers growth potential but requires monitoring of execution and market conditions.
United Airlines (UAL) trades at $125.32, up 1.26% today, with strong technical momentum and consistent earnings beats. The stock shows bullish moving averages and trades near resistance at $126. Fundamentals are solid, with revenue growth to $59.07B in 2025 and net income of $3.35B, supported by a low P/E of 11.83. Recent news highlights fuel cost management and merger speculation, though operational disruptions pose near-term risks.
Outlook remains positive with a consensus price target of $167.73, implying 34% upside. Opportunities include robust travel demand and cost controls, but risks involve volatile fuel prices, competitive pressure, and execution challenges. Analyst sentiment is strongly bullish with 66% buy ratings, though investors should monitor margin sustainability amid economic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About United Airlines Holdings Inc
United Airlines is a major U.S. network carrier. United's hubs include San Francisco, Chicago, Houston, Denver, Los Angeles, New York/Newark, and Washington, D.C. United operates a hub-and-spoke system that is more focused on international travel than legacy peers.
Read more on UAL →
